AveXis: ‘Speedy scale-up driven by Novartis acquisition’
With its own facilities, support from Novartis and now dedicated space at Catalent’s Paragon, AveXis says it has the most gene therapy manufacturing capacity in the industry. AveXis has inked a deal with contract development and manufacturing organization (CDMO) Paragon Gene Therapy to secure d ...
Plasmid manufacturer VGXI has entered a long-term supply agreement to support development of Geneos Therapeutics’ personalized cancer vaccines. ...
Avalon GloboCare has teamed with GE Healthcare to establish automated and standardized cell production capabilities to support its cellular immun ...
Sales grew 21% year-on-year at Sartorius’ H1 2019, while Repligen reported preliminary Q2 growth of nearly 50%. The bioprocessing sector ‘is ...
Servier has selected Pall Corporation as its exclusive technology and services provider at its biomanufacturing facility in Gidy, France.
The ...
Recent Tweets
-
RT @Dan5tanton: J&J has reported 57% year-on-year growth for its #multiplemyeloma monoclonal antibody Darzalex and is now hoping to… https://t.co/nt3kkGe1M6
6 days ago
-
RT @Dan5tanton: Kite will build a 67,000 square-foot facility within its parent company Gilead’s site in Oceanside, California to e… https://t.co/ucdPJg3fWA
7 days ago
-
Boehringer Ingelheim to buy cancer vaccine firm AMAL - The $365m acquisition is latest boost in the immune cell-di… https://t.co/Su3nVXiuVB
7 days ago
-
RT @Dan5tanton: ADC Bio has completed construction of a cleanroom in Wales, part of an $11m bioconjugation facility to serve demand… https://t.co/8ONhj1Js3U
1 week ago
